Company profile
uniQure N.V.
NASDAQ:QUREBiotechnology: Pharmaceutical Preparations
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06063850 | phase1_2 | recruiting | 2024-06-12 | 2026-11-30 | UniQure Biopharma B.V. | AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy |
| NCT02904772 | phase2 | withdrawn | 2016-10-01 | 2020-06-01 | UniQure Biopharma B.V. | Alipogene Tiparvovec for the Treatment of LPLD Patients |
| NCT03300453 | phase1_2 | completed | 2013-09-17 | 2019-11-27 | UniQure Biopharma B.V. | Intracerebral Gene Therapy in Children With Sanfilippo Type B Syndrome |
| NCT05243017 | phase1_2 | active_not_recruiting | 2021-10-07 | 2029-03-01 | UniQure Biopharma B.V. | Safety and Efficacy of AMT-130 in European Adults With Early Manifest Huntington's Disease |
| NCT04120493 | phase1_2 | active_not_recruiting | 2019-09-06 | 2029-06-01 | UniQure Biopharma B.V. | Safety and Proof-of-Concept (POC) Study With AMT-130 in Adults With Early Manifest Huntington's Disease |
FDA applications (0)
No records yet.